Management Non-Antimicrobial Oral for Acne Vulgaris Patient

Article Sidebar

PDF
Published: Aug 22, 2020
DOI: https://doi.org/10.53366/jimki.v8i2.117
Keywords:
acne, antibiotic, isotretinoin, spinorolactone, subantimicrobial

Main Article Content

Ayu Wulandari
Program Studi Profesi Dokter, Fakultas Kedokteran, Universitas Lampung
Dwi Indria Anggraini
Departemen Ilmu Penyakit Kulit dan Kelamin, Rumah Sakit Dr. H. Abdoel Moeloek – Fakultas Kedokteran, Universitas Lampung

Abstract

Introduction: Acne vulgaris (acne) is a non-infectious skin condition that is very common and often comes in dermatological practice. Because acne often appears chronic and can last for years, safe and effective long-term therapy is needed. Given the increasingly frequent antibiotic-resistant bacteria and the severity of the consequences if there is resistance, dermatologists are needed to maximize the use of non-antimicrobial therapy when treating patients with acne.


Objective: To find out which oral non-antibiotic drugs can be used for acne vulgaris therapy


Method: The article was prepared using the literature review method, involving 32 literature sourced from books and journals.


Results: The emergence and potential transfer of antibiotic resistance in skin microorganisms is of current concern in treatment especially in the context of dermatology where long-term treatment with antibiotics. Remarkably, non-antibiotic therapy in the form of isotretinoin - non-antimicrobial retinoids is effective in reducing or eradicating anaerobic Propionibacterium acnes that is causally involved in the pathogenesis of the Acne vulgaris complex.


Discussion: In this review of the literature we present data on the effects of the proper use of non-antimicrobial therapy for acne. There are various topical and oral treatment options that can be used gradually according to the severity and therapeutic response of the patient. Non-antimicrobial treatments can be very good at controlling acne, especially when used as maintenance therapy. While antibiotics have a role in the treatment of acne, they should not be used as monotherapy, and the use of old antibiotics is not recommended.


Conclusion: Some drugs whose hormonal mechanism can be oral non-antimicrobial drugs in the treatment of acne vulgaris


 


Keywords: Acne, Antibiotics, Isotretinoin, Spironolactone, Subantimicrobial

Article Details

How to Cite
Wulandari, A., & Anggraini, D. (2020). Management Non-Antimicrobial Oral for Acne Vulgaris Patient. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 8(2), 95-102. https://doi.org/10.53366/jimki.v8i2.117
Issue
Vol 8 No 2 (2020): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 8.2 Edisi Maret - Agustus 2020
Section
Article Review

References

1. Suh DH, Kwon HH. What’s new in the physiopathology of acne? Br J Dermatol. 2015 Jul;172(Supp 1):13–9.
2. Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241–8.
3. Ghosh S, Chaudhuri S, Jain VK, Aggarwal K. Profiling and hormonal therapy for acne in women. Indian J Dermatol. 2014 Mar;59(2):107–15.
4. Gollnick HPM, Dreno B. Pathophysiology and management of acne. J Eur Acad Dermatol Venereol. 2015 Jun;29(Suppl 4):1–2.
5. Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015;28(3):166–72.
6. Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015 Jul;172(Suppl 1):37–46.
7. Beylot C, Auffret N, Poli F, Claudel J-P, Leccia M-T, Del Giudice P, et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):271–8.
8. Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015 Jun;29(Suppl 5):1–7.
9. Roberts EE, Nowsheen S, Davis MDP, McEvoy MT, Newman CC, Sartori Valinotti JC, et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol. 2020 Feb;Feb(1):1–4.
10. Barker RA, Wilcox C, Layton AM. Oral Spironolactone for Acne Vulgaris in Adult Females: An Update of the Literature. Am J Clin Dermatol. 2020 Mar;1(1):2–6.
11. Layton AM, Eady EA, Whitehouse H, Del JQ, Fedorowicz Z, Zuuren EJ Van. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. Am J Clin Dermatol. 2017;18(2):169–91.
12. Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatology. 2015;151(9):941–4.
13. Lortscher D, Admani S, Satur N, Eichenfield LF. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. J drugs dermatology JDD. 2016 Jun;15(6):670–4.
14. Trivedi MK, Shinkai K, Murase JE. A Review of hormone-based therapies to treat adult acne vulgaris in women. Int J women’s dermatology. 2017 Mar 30;3(1):44–52.
15. Barros B, Thiboutot D. Hormonal Therapies For Acne. Clin Dermatol [Internet]. 2017;35(2):168–72. Available from: http://dx.doi.org/10.1016/j.clindermatol.2016.10.009
16. Słopień R, Milewska E, Rynio P, Męczekalski B. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Prz menopauzalny = Menopause Rev. 2018 Mar;17(1):1–4.
17. Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Dermatology. 2014;71(3):450–9.
18. Melnik BC. Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. Acta Derm Venereol. 2017;97:173–81.
19. Lee YB, Byun EJ, Kim HS. Potential Role of the Microbiome in Acne: A Comprehensive Review. J Clin Med. 2019;8(987):1–25.
20. Brar G, Grewal P, Korownyk C. Is less more with isotretinoin and acne ? Can Fam Physician. 2016;62(May):409.
21. Leyden JJ, Rosso JQ Del, Mcguigan KA. The Use of Isotretinoin in the Treatment of Acne Vulgaris. J Clin Aesthet Dermatol. 2014;7(2 Suppl):S3-21.
22. Webster G. Systemic Nonantibiotic Therapy in Acne and Rosacea. In: Biologic and Systemic Agents in Dermatology. New York: Springer International Publishing; 2018. p. 525–9.
23. Webster GF, Leyden JJ, Gross JA. Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol. 2014 Jun;13(6):665–70.
24. Henry D, Dormuth C, Winquist B, Carney G, Bugden S, Teare G, et al. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ. 2016;188(10):723–30.
25. Webster GFM. Isotretinoin: Mechanism of Action and Patient Selection. Semin Cutan Med Surg. 2015 Sep;34(5):S86-8.
26. Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-elera G, Kirby JS. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. JAMA Dermatology. 2016;152(1):35–44.
27. Hansen TJ, Lucking SM, Miller JJ, Kirby JS, Thiboutot DM, Zaenglein AL. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Dermatology. 2016;75(2):323–8.
28. Webster GF, Webster TG, Grimes LR. Laboratory tests in patients treated with isotretinoin: occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality. Dermatol Online J. 2017 May;23(5):13030/qt7rv7j80p.
29. Tintle SJ, Harper JC, Webster GF, Kim GK, Thiboutot DM. Safe Use of Therapeutic-Dose Oral Isotretinoin in Patients With a History of Pseudotumor Cerebri. JAMA dermatology. 2016 May;152(5):582–4.
30. Miziołek B, Bergler-czop B, Stańkowska A, Brzezińska-wcisło L. The safety of isotretinoin treatment in patients with bone fractures. Adv Dermatology Allergol. 2019;36(1):18–24.
31. Suuberg A. Psychiatric and Developmental Effects of Isotretinoin (Retinoid) Treatment for Acne Vulgaris. Curr Ther Res. 2019;90:27–31.
32. Huang Y, Cheng Y. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Dermatology. 2017;76(6):1068–76.